We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

42 hedge funds and large institutions have $303M invested in Xilio Therapeutics in 2021 Q4 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

5.09% more ownership

Funds ownership: 0% → 5.09% (+5.1%)

Holders
42
Holders Change
+42
Holders Change %
–
% of All Funds
0.65%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
42
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$47.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.8M
3
DM
Deerfield Management
New York
+$36.7M
4
RCM
RA Capital Management
Massachusetts
+$34.1M
5
RVM
RiverVest Venture Management
Missouri
+$24.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$44.9M +$47.8M +200,387 New
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$44.1M +$47M +197,096 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$41.1M +$43.8M +183,591 New
DM
4
Deerfield Management
New York
$33.7M +$36.7M +153,862 New
RCM
5
RA Capital Management
Massachusetts
$32M +$34.1M +143,016 New
RVM
6
RiverVest Venture Management
Missouri
$23.1M +$24.6M +102,960 New
RSCM
7
Rock Springs Capital Management
Maryland
$19.1M +$20.3M +85,078 New
AIIC
8
AJU IB Investment Company
South Korea
$10.7M +$11.4M +47,696 New
SCM
9
Soleus Capital Management
Connecticut
$7.64M +$8.13M +34,107 New
AG
10
Artal Group
Luxembourg
$7.2M +$7.66M +32,143 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$6.79M +$7.23M +30,302 New
HMC
12
Harvard Management Company
Massachusetts
$6.66M +$7.09M +29,719 New
Norges Bank
13
Norges Bank
Norway
$6.4M +$6.81M +28,571 New
BlackRock
14
BlackRock
New York
$5.18M +$5.52M +23,150 New
Fidelity International
15
Fidelity International
Bermuda
$3.5M +$3.72M +15,622 New
MIM
16
Monashee Investment Management
Massachusetts
$3.43M +$3.65M +15,304 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$2.15M +$2.29M +9,585 New
Northern Trust
18
Northern Trust
Illinois
$1.01M +$1.07M +4,502 New
State Street
19
State Street
Massachusetts
$947K +$1.01M +4,229 New
CCM
20
CAAS Capital Management
New York
$592K +$630K +2,644 New
GCM
21
Ghisallo Capital Management
Massachusetts
$480K +$511K +2,143 New
DKCM
22
Davidson Kempner Capital Management
New York
$458K +$494K +2,071 New
Marshall Wace
23
Marshall Wace
United Kingdom
$324K +$344K +1,442 New
Charles Schwab
24
Charles Schwab
California
$258K +$274K +1,150 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$228K +$242K +1,017 New
1
2

XLO Hedge Fund Activity: Q4 2021 in Review

42 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2021, worth a combined $303M.

Buyers outnumbered sellers: 42 funds opened new XLO positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $47.8M.

  • 42 institutional investors held Xilio Therapeutics (XLO) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $303M of Xilio Therapeutics stock for Q4 2021.
  • 42 funds opened new Xilio Therapeutics positions in Q4 2021 and 0 closed out, a net change of +42 holders.
  • The largest Xilio Therapeutics buyer in Q4 2021 was Bain Capital Life Sciences Investors, an estimated $47.8M added.

Based on aggregated 13F filings for Q4 2021.